Pacira BioSciences (PCRX) Inventory Average (2016 - 2025)
Pacira BioSciences has reported Inventory Average over the past 15 years, most recently at $155.3 million for Q4 2025.
- Quarterly results put Inventory Average at $155.3 million for Q4 2025, up 30.95% from a year ago — trailing twelve months through Dec 2025 was $155.3 million (up 30.95% YoY), and the annual figure for FY2025 was $139.1 million, up 21.12%.
- Inventory Average for Q4 2025 was $155.3 million at Pacira BioSciences, up from $152.9 million in the prior quarter.
- Over the last five years, Inventory Average for PCRX hit a ceiling of $155.3 million in Q4 2025 and a floor of $64.6 million in Q1 2021.
- Median Inventory Average over the past 5 years was $100.3 million (2023), compared with a mean of $103.2 million.
- Biggest five-year swings in Inventory Average: soared 57.27% in 2022 and later decreased 9.37% in 2023.
- Pacira BioSciences' Inventory Average stood at $82.9 million in 2021, then increased by 16.35% to $96.4 million in 2022, then increased by 4.15% to $100.4 million in 2023, then grew by 18.06% to $118.6 million in 2024, then soared by 30.95% to $155.3 million in 2025.
- The last three reported values for Inventory Average were $155.3 million (Q4 2025), $152.9 million (Q3 2025), and $141.0 million (Q2 2025) per Business Quant data.